Patents by Inventor Omid Vafa

Omid Vafa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZED Fc VARIANTS
    Publication number: 20240026023
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants
    Patent number: 11820830
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: November 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA
    Publication number: 20230257473
    Abstract: Multi-specific, human heavy chain antibodies (e.g., UniAbs™) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 17, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Harbani Malik, Ute Schellenberger, Omid Vafa, Shelley Force Aldred
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20230203161
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 29, 2023
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim Van Schoofen, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20220332820
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: November 23, 2021
    Publication date: October 20, 2022
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • Multispecific heavy chain antibodies with modified heavy chain constant regions
    Patent number: 11390681
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: July 19, 2022
    Assignee: TeneoTwo, Inc.
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Udaya Rangaswamy
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20220089729
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: June 14, 2021
    Publication date: March 24, 2022
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Udaya Rangaswamy
  • Multispecific heavy chain antibodies with modified heavy chain constant regions
    Patent number: 11186639
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: November 30, 2021
    Assignee: TENEOONE, INC.
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20210340255
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 4, 2021
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • Antibody Fc Mutants with Ablated Effector Functions
    Publication number: 20210155711
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Inventors: Stephen McCarthy, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
  • OPTIMIZED Fc VARIANTS
    Publication number: 20210139600
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: July 29, 2020
    Publication date: May 13, 2021
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Antibody Fc mutants with ablated effector functions
    Patent number: 10894836
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: McCarthy Stephen, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
  • Fc variants with increased affinity for Fc?RIIc
    Patent number: 10584176
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 10, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Fc Variants with Increased Affinity for FcyRIIc
    Publication number: 20190071512
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 7, 2019
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Optimized Fc variants and methods for their generation
    Patent number: 10183999
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants and methods for their generation
    Patent number: 10184000
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • NOVEL IMMUNOGLOBULIN VARIANTS
    Publication number: 20180360981
    Abstract: The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 20, 2018
    Inventors: Gregory Alan Lazar, Bassil Dahiyat, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Antibody Fc Mutants with Ablated Effector Functions
    Publication number: 20180319893
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: McCarthy Stephen, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
  • Fc variants with increased affinity for FcyRIIc
    Patent number: 10113001
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 30, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Antibody Fc mutants with ablated effector functions
    Patent number: 10053513
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: August 21, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Stephen McCarthy, Bernard Scallon, Susan Tam, William Strohl, Omid Vafa